Go Pro
TSE:EDT

Spectral Medical Q3 2024 Earnings Report

Spectral Medical logo
C$1.17 -0.01 (-0.85%)
As of 10/2/2026 03:58 PM Eastern

Spectral Medical EPS Results

Actual EPS
-C$0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Medical Revenue Results

Actual Revenue
$0.50 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Medical Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Friday, November 8, 2024
Conference Call Time
2:30AM ET

Earnings Documents

Spectral Medical Earnings Headlines

They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Spectral Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Medical and other key companies, straight to your email.

About Spectral Medical

Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin¿ ('PMX'). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's FDA cleared Endotoxin Activity Assay (EAA¿), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold worldwide to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.

View Spectral Medical Profile